Alemtuzumab-associated diffuse alveolar damage - a case report

BMC Neurol. 2020 Sep 23;20(1):357. doi: 10.1186/s12883-020-01934-7.

Abstract

Background: Identifying causes of alemtuzumab induced respiratory symptoms in Multiple Sclerosis (MS) patients is crucial.

Case presentation: We report a case of diffuse alveolar damage (DAD) in a patient with MS after the first course of alemtuzumab treatment. A 42-year-old female developed progressive non-productive cough and exertional dyspnea 2 months after alemtuzumab treatment. DAD was diagnosed histopathologically by lung biopsy. The patient recovered completely, alemtuzumab was not continued.

Conclusions: Our case highlights another pathomechanism for non-infective lung-disorders in alemtuzumab treated MS patients. DAD is a potential, albeit rare side effect of alemtuzumab, broadening the spectrum of non-infective lung disorders that should be considered in the diagnostic work-up.

Keywords: Alemtuzumab; Case report; Diffuse alveolar damage; Multiple sclerosis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Alemtuzumab / adverse effects*
  • Antineoplastic Agents, Immunological / adverse effects*
  • Female
  • Humans
  • Lung Diseases, Interstitial / chemically induced*
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Pulmonary Alveoli / pathology*

Substances

  • Antineoplastic Agents, Immunological
  • Alemtuzumab